Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer

被引：0
|
作者：
Hohaus, S
Wallwiener, D
Martin, S
Voso, MT
Huober, J
Fersis, N
Bastert, G
Haas, R
机构：
[1] Heidelberg Univ, Dept Internal Med 5, D-69115 Heidelberg, Germany
[2] Heidelberg Univ, Dept Gynecol, D-69115 Heidelberg, Germany
来源：
SEMINARS IN ONCOLOGY | 1998年 / 25卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 11
页数：5
相关论文
共 50 条
  • [21] Low toxicity of high-dose CTM followed by autologous stem cell reinfusion for high-risk breast cancer
    Kruger, WH
    Kroger, N
    Kolbe, K
    Huber, C
    Gieseking, F
    Janicke, F
    Konigsmann, M
    Berdel, WE
    Kerschgens, C
    Mayr, AC
    Schafer-Eckert, K
    Wandt, H
    Schultze, W
    Fuss, H
    Metzner, B
    Illiger, HJ
    Frickhofen, N
    Mobus, V
    Hossfeld, DK
    Jonat, W
    Zander, AR
    BONE MARROW TRANSPLANTATION, 1998, 21 : S62 - S62
  • [22] Long-term toxicity of high-dose sequential chemotherapy with autologous hematopoietic stem cells support in very high-risk early breast cancer patients (pts)
    Bernardi, A.
    Zamagni, C.
    Quercia, S.
    Massari, F.
    Cacciari, N.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer Reply
    Steenbruggen, Tessa G.
    Steggink, Lars C.
    Sonke, Gabe S.
    JAMA ONCOLOGY, 2020, 6 (08) : 1300 - 1300
  • [24] Persistence of isolated tumor cells in patients with breast cancer after sequential high-dose therapy with peripheral blood stem cell transplantation (PBSC).
    Hohaus, S
    Funk, L
    Brehm, M
    Abdallah, A
    Murea, S
    Kaul, S
    Haas, R
    BLOOD, 1996, 88 (10) : 501 - 501
  • [25] High-dose therapy with hemopoietic stem cell support for high risk breast cancer. A pilot study in 31 patients
    PerezCarrion, R
    Tomas, JF
    PerezManga, G
    Holgado, J
    SanchoCuesta, F
    GonzalezBaron, M
    Escudero, A
    LopezLorenzo, JL
    LopezPascual, J
    FernandezRanada, JM
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1125 - 1125
  • [26] Toxicity profile of tandem high-dose chemotherapy with epirubicin, cyclophosphamide and thiotepa (ECT) and stem-cell support in high-risk breast cancer
    Eimermacher, H
    Frick, M
    Kalitschke, W
    Lindemann, HW
    Nitz, U
    Adomeit, A
    Souchon, R
    Scholten, T
    BONE MARROW TRANSPLANTATION, 1998, 22 : S12 - S12
  • [27] High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
    Cottu, PH
    Extra, JM
    Espie, M
    Marolleau, J
    de Roquancourt, A
    Makke, J
    Miclea, JM
    Laurence, V
    Mayeur, D
    Lerebours, F
    Cuvier, C
    Marty, M
    BRITISH JOURNAL OF CANCER, 2001, 85 (09) : 1240 - 1246
  • [28] High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
    P H Cottu
    J M Extra
    M Espie
    J P Marolleau
    A de Roquancourt
    J Makke
    J M Miclea
    V Laurence
    D Mayeur
    F Lerebours
    C Cuvier
    M Marty
    British Journal of Cancer, 2001, 85 : 1240 - 1246
  • [29] High-dose therapy with peripheral blood progenitor cell support (PBPC) for the treatment of advanced breast cancer
    Fersis, N
    Haas, R
    Wallwiener, D
    Hohaus, S
    Huober, J
    Bastert, G
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 661 - 661
  • [30] High-dose therapy with peripheral blood progenitor cell support (PBPC) for the treatment of advanced breast cancer
    Fersis, N
    Haas, R
    Wallwiener, D
    Hohaus, S
    Fruhauf, S
    Bastert, G
    BREAST, 1997, 6 (05): : 321 - 321
12345